UBS Warburg to lead biggest Neuer Markt biotech IPO

UBS Warburg is set to lead-manage the largest ever initial public offering on the Neuer Markt for a biotechnology company when it launches the IPO for Genmab next month.

The Genmab IPO takes biotech issues in Europe since July past the €1bn ($880m) mark, reinforcing the strength of the sector and investors' insatiable appetite for the high-quality paper.

WSJ Logo
Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With TrumpExternal link

Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With Trump